logo-loader
viewGilead Sciences, Inc.

Gilead slaps multi-thousand-dollar price tag on coronavirus treatment remdesivir

The pharma giant intends to charge developed countries US$2,340 for a five-day treatment, while other parts of the world can access generic versions

Gilead Sciences, Inc. - Gilead slaps multi-thousand-dollar price tag on coronavirus treatment remdesivir

Gilead Sciences Inc (NASDAQ:GILD) has announced it will charge thousands of dollars for its investigational drug remdesivir, temporarily approved in certain countries as coronavirus treatment.

In the US, a five-day course will cost US$3,120 for patients with private health insurance, while those on government programmes such as Medicaid will be charged US$2,340.

READ: Gilead Sciences' remdesivir shows improvement in coronavirus patients with moderate pneumonia

The pharma giant said this price, which amounts to US$390 per vial, will be offered to all governments in developed countries around the world where remdesivir is approved or authorised for use.

Less wealthy countries will be able to receive a generic version, as Gilead inked licensing agreements with five manufacturers.

Clinical trials showed that the antiviral can help patients with moderate pneumonia to recover faster compared to the standard of care over a 5-day course, while the 10-day treatment did not show statistical significance.

It is also being evaluated in combination with Roche’s arthritis treatment Actemra for severe coronavirus cases.

Shares rose 2% to US$76.06 on Monday after open.

Quick facts: Gilead Sciences, Inc.

Price: 76.68 USD

NASDAQ:GILD
Market: NASDAQ
Market Cap: $96.19 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Jubilee Metals CEO welcomes 54% growth in first half operational earnings

Jubilee Metals Group PLC's (LON:JLP) Leon Coetzer caught up with Proactive London's Andrew Scott after reporting its sixth consecutive six-monthly period of double digit growth - posting a 54% increase in first-half earnings to £12.8mln. The company was also able to boost revenue by 18% to...

14 hours, 18 minutes ago

2 min read